VIRX stock icon

Viracta Therapeutics
VIRX

$0.59
9.79%
 

About: Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Employees: 40

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

72% more capital invested

Capital invested by funds: $5.56M [Q4 2023] → $9.58M (+$4.02M) [Q1 2024]

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

1.32% less ownership

Funds ownership: 25.24% [Q4 2023] → 23.92% (-1.32%) [Q1 2024]

5% less funds holding

Funds holding: 42 [Q4 2023] → 40 (-2) [Q1 2024]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
578%
upside
Avg. target
$7.20
1,120%
upside
High target
$13
2,103%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Oppenheimer
Hartaj Singh
1,764%upside
$11
Outperform
Maintained
23 May 2024
Oppenheimer
Hartaj Singh
2,103%upside
$13
Outperform
Maintained
17 Apr 2024
HC Wainwright & Co.
Robert Burns
578%upside
$4
Buy
Reiterated
16 Apr 2024
HC Wainwright & Co.
Robert Burns
578%upside
$4
Buy
Reiterated
12 Mar 2024
HC Wainwright & Co.
Robert Burns
578%upside
$4
Buy
Maintained
5 Jan 2024

Financial journalist opinion